By studying biomarkers known to be involved in gastrointestinal cancers, researchers at the Johns Hopkins Kimmel Cancer ...

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by distinct histological subtypes and a poor prognosis. Among these, the micropapillary pattern, typically observed ...

Lisata Therapeutics (NASDAQ:LSTA) lost ~38% in the premarket on Wednesday after the cancer drug developer shared results from a mid-stage trial for its main asset, certepetide, in patients with ...

The following is a summary of “Biological characterization and clinical significance of cuproptosis-related genes in lung ...

Ultrasensitive ctDNA detection with NeXT Personal shows 81% sensitivity in early-stage lung adenocarcinoma, improving ...

Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase I for Adenocarcinoma.

BERGEN, Norway, Jan. 7, 2025 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for lung ...

Previously, clinical research findings on cadonilimab in the treatment of various malignancies have been published in internationally renowned journals such as The Lancet, The Lancet Oncology, Nature ...

Pharmacogenomics. 2014;15(11):1507-1518. MEK/CDK4 PD-0325901 (MEKi) + palbociclib (CDK4i) NCT02022982 MEK/CDK4 Trametinib (MEKi) + palbociclib (CDK4i) NCT02065063 ...

With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s ...